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Introduction. Several point-of-care tests (POCT) are available for the diagnosis of bladder cancer (BC). We evaluate the impact
of HU (hematuria) on performance of POCTs. Materials and Methods. Urine from 10 donors was diluted with blood from
0.5 to 0.00625%. BladderCheckR,B T A s t a t R,B C M R, and BTAR tests were applied. Tests were additionally conducted in 54
patients with HU. HU was stratiﬁed according to the amount of erythrocytes (RBC)/μL using two systems: (1) no HU; mild
microscopic HU; severe microscopic HU; gross HU; (2) I <25RBCs; <250 II; ≥250 III. Results were compared to HU status and
histopathology. Results. Gross HU became evident between 2090RBCs/μL and 1065/μL. Addition of blood led to default tests in all
4: BladderCheckR 0.25%; BCM 0.025%, BioNexia 0.00625%, and BTAstat <0.00625%. Rates of false positives for BladderCheck,
BTAstat, BCM, and BioNexia were 5.9, 11.8, 0, and 1.8% without HU and 0, 66.7, 44.4, and 66.7% with HU. BTAstat, BCM, and
BioNexia were independently inﬂuenced by HU (P<0.0002). Conclusions. NMP22-BladderCheck was most resistant to blood.
The diagnostic yield of all others was signiﬁcantly inﬂuenced by HU. A well-deﬁned HU grading helps to deﬁne limits of HU for
a reliable interpretation of BC-POCTs.
1.Introduction
Bladdercancer(BC)presentsasamalignancywithincreasing
incidence, a signiﬁcant impact on quality of life, and the
highest lifetime treatment costs per patient [1]. Early detec-
tion to prevent progressive disease remains the challenge of
the disease. Since speciﬁc symptoms are lacking and most
patients present with unspeciﬁc hematuria (HU), invasive
measures are still needed for ultimate diagnosis. Hence,
cystoscopy is still the gold standard in the diagnostic workup
of BC [2]. Noninvasive tests are restricted to urine markers.
Beside urine cytology, molecular markers evolved within
recent years and play an emerging role in diagnosis and
monitoring of BC [3]. However, the diagnostic accuracy of
cytology and of molecular markers remains unsatisfactory.
Due to insuﬃcient discriminatory power, urine markers are
still not able to replace cystoscopy [4]. Recently, oﬃce-based
pointofcaretest(POCT)systemsbecameavailable[5].They
are particularly useful for oﬃce physicians without direct
access to cost-intensive laboratory equipment.
Several sources for limited diagnostic yield, mainly for
limited speciﬁcity, have been identiﬁed. Whereas urinary
tract infection, mechanical stress due to instrumented uri-
narysamplingandotherscouldbedeterminedasinﬂuencing
factors for several tests [6–8], HU has not been extensively
studied yet [6, 9]. Even though a high percentage of patients
presents with HU, its drawbacks on POCTs are poorly
deﬁned. HU, however, covers a wide spectrum reaching from
single RBCs to apparent gross HU. Even though others have
reported on the interaction of blood and urine-based tests
for BC, there are no clear-cut reports available about the
impact of diﬀerent grades of HU on such tests [10–12].
Furthermore, evidence is even more limited when focusing
on the susceptibility of POCTs to HU.
Aim of the study was to investigate the inﬂuence of well-
deﬁned grades of HU on four commercially available POCTs2 Advances in Urology
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Figure 1: (a) False positive results of POCTs out of ﬁve patients per setting in diﬀerent dilutions. HU: hematuria. (b) Rates of false positive
test results and grades of hematuria in BC patients.
in an experimental setting as well as in patients suspected to
have BC.
2.MaterialsandMethods
2.1. In Vitro Study. Ten subjects who presented for rou-
tine checkup with no evidence of BC or other disease
were included. Median age was 44 (range 21–55) years, 6
were males, and 4 were females. Midstream urine of at
least 100mL was collected in all. Cytology, dipstick, and
microscopy of the investigated urine specimen were incon-
spicuous. Patients did not have signs of uro-/nephrolithiasis,
urinary tract infection, or cystitis. The study received
approvalbythelocalIRB(no.400/2009A).Autologousblood
w a sd r a w na n ds t o r e di na nE D T At u b e .S u b s e q u e n t l y ,a
hemogram was performed. By addition of 0.2mL whole
blood to 19.8mL urine, a 1.0% v/v dilution was generated,
and, by performing serial dilutions, additional concentra-
tions were generated as shown in Figure 1.T oa l l o wf o r
potential interactions between urine and blood and to gen-
erate grades of HU, urines were incubated for ﬁve minutes
afterbloodaddition.Ineverydilution,adipsticktestwasper-
formed and RBCs were counted using a Neubauer-improved
counting chamber. NMP22 BladderCheckR (Matritech,
Freiburg, FRG), BTAstatR (Polymedco, Cortlandt Manor,
NY,USA),BioNexia-BTAR (BioNexia, G¨ ottingen, Germany),
and BCMR (Ulti med GmbH, Ahrensberg, Germany) were
performed simultaneously according to the manufacturer’s
recommendations within 30min after urine sampling.
2.2. Clinical Study. 54 consecutive patients were enrolled
between 06/2009 and 11/2009. Patients were either suspi-
cious of having BC or had histologically proven muscle-
invasive BC. The ﬁrst group subsequently underwent cys-
toscopy and the second group had radical cystectomy. 54
patients before cystoscopy (n = 48) or cystectomy (n =
6) were investigated. Median age was 68.5 (range 42–90)
years, 42 were males, and 12 were females. No patient had
mechanical manipulation of the urethra or bladder within
the last seven days before specimen harvesting. Patients with
a recent history of urolithiasis, urinary tract infection, cysti-
tis, or previous Mitomycin/BCG installation were excluded.
Dipstick and urine microscopy were performed, and the
presence of HU was documented.
HU was subclassiﬁed by dipstick, urine microscopy,
and visual assessment: no RBCs neither in dipstick nor
in microscopy = no HU; RBCs 10–250/μL in dipstick and
microscopy = mild micro-HU; >250/μL RBCs in dipstick
and microscopy = severe micro-HU; visible blood colour-
ing = gross HU. Since initial results had already shown
considerable diﬀerences already in low-grade HU, HU was
further subclassiﬁed in a second step: RBCs ≤25 (including
0) = Grade I, <25 RBCs <250 = Grade II, and RBCs ≥250
including gross HU = Grade III.
The amount of false positive tests was comparatively
investigated for all POCTs. For the patients’ cohort, the rela-
tion of HU and the presence or absence of BC were analyzed
by contingency tables. False positive results were further
associated with the predeﬁned grades of HU. Multivariate
analysis was done to assess the independent impact of HU
on the diagnosis of BC.
3. Results
3.1. In Vitro Results. The serial dilutions (0.5%-0.25%-
0.125%-0.0625%-0.0025%-0.00125%-0.000625%) of the
harvestedurineyieldedthefollowingvalues:21.200RBCs/μL
= 0.5%; 10.730RBCs/μL = 0.25%; 4.080RBCs/μL = 0.125%;
2.090RBCs/μL = 0.0625%; 1.065RBCs/μL = 0.0025%; 326
RBCs/μL = 0.00125%; 168RBCs/μL = 0.000625%. Dipstick
RBC counts correlated well to the microscopy. The threshold
level from mild to severe microscopic HU was found to be
between a dilution of 0.0125% and 0.00625%. At 0.0625%
(corresponding to 2090RBCs/μL), but not at 0.025%
(1065/μL), gross HU was clearly notable. The addition ofAdvances in Urology 3
Table 1: Contingency table for the presence of bladder cancer and
graded hematuria.
Counts
Total %
Column %
Line %
No bladder
cancer
Bladder
cancer
No hematuria
17
31,48
65,38
77,27
5
9,26
17,86
22,73
22
40,74
Hematuria
9
16,67
34,62
28,13
23
42,59
82,14
71,88
32
59,26
Grades of hematuria
Grade I
19
35,19
73,08
61,29
12
22,22
42,86
38,71
31
57,41
Grade II
4
7,41
15,38
66,67
2
3,70
7,14
33,33
6
11,11
Grade III
3
5,56
11,54
17,65
14
25,93
50,00
82,35
17
31,48
Total 26
48,15
28
51,85 54
blood led to default tests in all 4 POCTs. However, the level
of dilution was diﬀerent: NMP22-BladderCheckR was the
most stable test system at 0.25% (10.730/μL) followed by
BCM, BioNexia, and BTAstat. BCM was altered at 0.025%
(1065/μL), BioNexia at 0.00625% (168/μL), and BTAstat at
<0.00625% (<168/μL) for (Figure 1(a)).
3.2. Patients’ Results. Of the patients before cystoscopy, 8
presentedwithahistoryofBCduringfollowup .AfterTURor
cystectomy, 28/54 patients (51.9%) were found to have BC:
17 × Ta, 4 × T1, 5 × T ≥ 2, and 2 × CIS. G1 tumors were
f o u n di n7 ,G 2i n1 3 ,a n dG 3i n6p a t i e n t s .
At the time of enrolment, 32/54 (59.3%) of the patients
hadHU.Accordingtothepredeﬁnedcriteria,20subjectshad
mild microscopic HU, 8 had severe microscopic HU, and 4
had gross HU. When the adjusted grading for HU was used,
31 patients had grade I (including no HU) HU, 6 grade II
HU, and 17 grade III (including gross HU). Contingency
tablesofHUandpresenceofBCareshowninTable 1.Results
fromcontingencyanalysisofgraduatedHUandfalsepositive
tests are shown in Figure 1(a). In the group of patients with
proven BC, 12 had grade I HU (42.9%), 2 grade II HU
(7.1%), and 14 grade III (50.0%, Table 1).
17/26 (65.4%) patients who had no BC presented
without HU. Of those, 1 (5.9%), 2 (11.8%), 0 (0.0%), and 2
(11.8%) patients had false positive results of BladderCheck,
BTAstat, BCM, and BioNexia, respectively. False positive test
results were seen in 9/26 patients who had no BC but HU: 0
(0%)forBladderCheck, 6 (66.7%) forBTAstat,4 (44.4%) for
BCM, and 6 (66.7%) for BioNexia. 2/26 patients presented
withoutBCbuthadseveremicroscopicHUorgrossHU,and
false positive results were seen in 0 (0%) for BladderCheck
and 2 (100.0%) patients for BTAstat, BCM, and BioNexia,
respectively. One patient presenting without BC but gross
HU revealed a negative BladderCheck, whereas BTA, BCM,
and BioNexia were positive.
3.3.ClassiﬁcationofHUaccordingtoGrade. Patientspresent-
ingwithoutBCwerefoundtohavevariousdegreesofHU:19
× grade 1 (73.1% of all 26 patients without BC), 4 × grade 2
(15.4%), and 3 × grade 3 HU (11.5%, Table 1). False positive
results were documented for BladderCheck, BTAstat, BCM,
and BioNexia (Figure 1(a)). At grade 1, HU in 1 (5.3%), 3
(15.8%), 0 (0%), and 3 (15.8%) of 19 patients; at grade 2,
HU in 0 (0%), 2 (50.0%), 1 (25.0%), and 2 (50.0%) of 4
patients; at grade 3, HU in 0 (0%), 3 (100%), 3 (100.0%),
and 3 (100.0%) of 3 patients, respectively, (Figure 1(a)).
In multivariate analysis, HU was an independent inﬂu-
encing variable for the results of BTAstat, BCM, and
BioNexia (P = 0.0002, <0.0001, and <0.0001). The NMP22-
BladderCheck test was not signiﬁcantly inﬂuenced by HU
(P = 0.77).
4. Discussion
Molecular urine tests are promising biomarkers for BC.
However, they are still not well established in daily clinical
routine and in the standard diagnostic workup of BC [2].
In contrast to other molecular tests that require elaborate
molecular methodology (e.g., FISH, immunocytology, or
ELISA), new POCT systems provide the opportunity to
be applied by oﬃce physicians without direct access to
expensive laboratory equipment. However, for being broadly
used, adequate test speciﬁcity and sensitivity is at least as
important as the feasibility.
Several studies have been published comparing accuracy
of various POCTs. Sensitivity and speciﬁcity are widely
varying within diﬀerent publications [3, 5, 13–15]. These
variationsmaybeexplainedbyinherentinﬂuencingvariables
such as infection or hematuria. Data on such interferences
are scarce, and experimental data are even less common.
Hence, we designed the present study to investigate the
impact of such a variable on 4 of the most commonly
used POCTs for BC detection. An experimental model
for diﬀerent grades of HU was constructed allowing for
accurate assessment of the inﬂuence of the RBC count on
the test system. Moreover, a threshold for default could be
determined for all POCTs. Since all 4 POCTs adhere to
diﬀerent principles, it is not very surprising that there were
clear diﬀerences between the investigated test systems. The
BladderCheck showed a positive result only in one subject
at a dilution of 0.5% and was then negative for all following
dilutions.Allothertestswerepositivethroughout0.25%,and
theBCMtestshowedonenegativeresultoutofﬁveat0.125%
and became totally negative at 0.025%. Gross HU leads to
false positive results in BTAstat and Bionexia, whereas the4 Advances in Urology
BladderCheck showed no false positive results under such
circumstances. The BCM test was indeterminate being only
partly susceptible to HU. In microscopic HU conditions,
only BladderCheck and BCM remained constantly negative
whereasBTAstatandBioNexiawerenotresistanttoevenvery
small amounts of blood in the urine.
Gross HU is a clear indication to perform cystoscopy and
upper tract imaging. However, there is no well-deﬁned and
widely adopted algorithm for the evaluation of microscopic
HU. As many practicing physicians are hesitant to recom-
mend cystoscopy to such patients due to its invasiveness,
POC tests are of particular interest serving as an additional
decision tool.
The results of the in vitro setting were further validated
in a consecutive cohort of patients. In the HU group, no
BladderCheck was false positive, the BCM showed lower
susceptibility to blood than BTAstat and BioNexia. In
contrast to the in vitro setting, even severe microscopic HU
resulted in a 100% false positivity of the BCM test. When
HU was graded from I to III, the latter test showed improved
performance with a rate of only 50% false positives below
grade III.
NMP22 was reported to be overexpressed by malignant
urothelial cells and released into the urine by apoptotic cells
[16]. Therefore, other nonmalignant conditions producing
apoptotic cells may provide NMP22 in the urine [3]. As
RBCs do not have a nucleus, they cannot increase NMP22
directly in HU samples. Possible explanations for the impact
of RBC might be membrane factors causing a cross-reaction
or related serum proteins [11]. The remaining investigated
assays detect the human complement factor H and related
protein (the Bladder Tumour-associated Antigen) which is
reported to be a marker for BC [17]. Blood-bound H-related
protein could be responsible for false positive assays [12].
Experimental spiking of blood into urine was already
introduced by other groups. In contrast to our study,
which focuses on the performance of POCTs, Ats¨ ue t
al. investigated the quantitative NMP22-ELISA [11]. They
conducted serial dilutions and found artiﬁcially increased
results above the ELISA cut-oﬀ level between 0.2 and 0.02%
blood.Comparedtothepresentresults,theirreportindicates
that the quantitative test might shift positive earlier than the
POC test. However, they refered their dilutions to high ﬁeld
counts and did not determine exact RBC concentrations.
Yokoyama et al. [18] provided ﬁrst data on the Blad-
derCheck: they reported false positive results above 105
RBCs/μL. Both studies conﬁrm that the BladderCheck is
resistant to microscopic HU being an extremely frequent
condition in aﬀected patients. Oge et al. [12] used relatively
high concentrations of blood admixtures and found a 20%
false positivity of the BTAstat at a dilution of 1:2000
(0.05%);however,thisdilutionmightbeclosetomicroscopic
HU. The results of both were conﬁrmed by our results.
Schwentner et al. presented data about the inﬂuence
of HU on results of urine tests in a cohort of more than
2000 patients. They conﬁrmed a clear inﬂuence of HU on
the performance of the NMP22-ELISA. Moreover, a clear
inﬂuence of HU on immunocytology and even cytology was
reported [19]. The fact that in our study test systems did
not show uniform results at one dilution threshold (either
all positive or all negative) also indicates additional factors in
urine that impact on the test outcome.
Grading of HU is increasingly addressed by studies
evaluating urine tests. Pesch et al. suggested in a prospective
study a semiquantitative recording of urine RBCs to more
accurately interpret positive NMP22 (ELISA) results [10].
The dilution experiments performed in the present work
allow for quantifying HU into distinct subgroups: the upper
limit of the dipstick is 250 RBCs/μL. However, gross HU
was not visible before 2000/μL. All tests have been shown to
perform clearly better below a 250 RBC dipstick result.
The limitation of our study is a relatively low number of
patients. Moreover, as our study only evaluated the impact
of HU on false positive results, we cannot comment on
the inﬂuence of sensitivity on the rate of false positivity.
NMP22 is a strong, independent predictor of bladder cancer.
Integration of NMP22 into clinical decision making helps
avoid unnecessary cystoscopies [20].
This is theﬁrststudy comparing theimpact ofHUonthe
performance of 4 POC urine tests for BC in an experimental
setting. We found a correlation between the false positive
rate of BTAstat, BMC, and BioNexia tests and urinary blood
burden. The diagnostic properties of BladderCheck were not
inﬂuenced by HU. Our ﬁndings may contribute to a more
comprehensive understanding of HU grading providing a
clinical classiﬁcation of HU. A well-deﬁned HU grading
may help to deﬁne appropriate limits of HU for a reliable
application and interpretation of BC-POCTs in the oﬃce
setting.
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